Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BALANCE-DM2: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) in Latin American Adults With Type 2 Diabetes Mellitus

NCT07628985 is registered in ClinicalTrials.gov with Carnot Laboratories as lead sponsor.

NCT NCT07628985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07628985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BALANCE-DM2: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) in Latin American Adults With Type 2 Diabetes Mellitus
Lead sponsor
Carnot Laboratories
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
October 31, 2027
Enrollment
374 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus (t2dm)